Close

Roth Cuts PT on Synta Pharma (SNTA) to $20; Still Attractively Priced Given Ganetespib Potential

Go back to Roth Cuts PT on Synta Pharma (SNTA) to $20; Still Attractively Priced Given Ganetespib Potential

Form 8-K SYNTA PHARMACEUTICALS For: Feb 05

February 5, 2015 5:23 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

... More